QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:KALV

KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis

$14.03
-0.11 (-0.78%)
(As of 03/4/2024 ET)
Today's Range
$13.86
$14.27
50-Day Range
$11.37
$16.04
52-Week Range
$6.26
$16.88
Volume
414,160 shs
Average Volume
884,093 shs
Market Capitalization
$484.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.33

KalVista Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
87.7% Upside
$26.33 Price Target
Short Interest
Bearish
12.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.97
Upright™ Environmental Score
News Sentiment
0.63mentions of KalVista Pharmaceuticals in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
$5.81 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.09) to ($2.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.15 out of 5 stars

Medical Sector

167th out of 960 stocks

Pharmaceutical Preparations Industry

71st out of 440 stocks


KALV stock logo

About KalVista Pharmaceuticals Stock (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

KALV Stock Price History

KALV Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
See More Headlines
Receive KALV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/07/2023
Today
3/04/2024
Next Earnings (Estimated)
3/14/2024
Fiscal Year End
4/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KALV
Employees
118
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$26.33
High Stock Price Target
$35.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+87.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-92,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.71 per share

Miscellaneous

Free Float
30,308,000
Market Cap
$484.88 million
Optionable
Optionable
Beta
0.90
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Thomas Andrew Crockett M.B.A.Mr. Thomas Andrew Crockett M.B.A. (Age 49)
    CEO & Director
    Comp: $914.61k
  • Mr. Benjamin L. Palleiko (Age 58)
    President, Chief Business Officer & CFO
    Comp: $707.1k
  • Dr. Christopher M. Yea Ph.D. (Age 60)
    Chief Development Officer
    Comp: $640.23k
  • Dr. Edward P. Feener Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $506k
  • Mr. Ryan Baker
    Head of Investor Relations
  • Mr. Brian Krex J.D. (Age 56)
    General Counsel
  • Jarrod Aldom
    Vice President of Corporate Communications
  • Ms. Rachel M. Morten
    Senior Vice President of Regulatory Affairs & QA
  • Dr. Michael D. Smith Pharm.D. (Age 44)
    Senior Vice President of Development
  • Dr. Paul K. Audhya M.B.A. (Age 51)
    M.D., Chief Medical Officer














KALV Stock Analysis - Frequently Asked Questions

Should I buy or sell KalVista Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KALV shares.
View KALV analyst ratings
or view top-rated stocks.

What is KalVista Pharmaceuticals' stock price target for 2024?

3 equities research analysts have issued 12 month target prices for KalVista Pharmaceuticals' stock. Their KALV share price targets range from $20.00 to $35.00. On average, they anticipate the company's stock price to reach $26.33 in the next year. This suggests a possible upside of 87.7% from the stock's current price.
View analysts price targets for KALV
or view top-rated stocks among Wall Street analysts.

How have KALV shares performed in 2024?

KalVista Pharmaceuticals' stock was trading at $12.25 at the beginning of 2024. Since then, KALV shares have increased by 14.5% and is now trading at $14.03.
View the best growth stocks for 2024 here
.

Are investors shorting KalVista Pharmaceuticals?

KalVista Pharmaceuticals saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 2,990,000 shares, an increase of 21.1% from the January 31st total of 2,470,000 shares. Based on an average daily volume of 686,700 shares, the days-to-cover ratio is presently 4.4 days. Currently, 12.4% of the shares of the company are short sold.
View KalVista Pharmaceuticals' Short Interest
.

When is KalVista Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our KALV earnings forecast
.

How were KalVista Pharmaceuticals' earnings last quarter?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) announced its quarterly earnings results on Thursday, December, 7th. The specialty pharmaceutical company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by $0.04.

What other stocks do shareholders of KalVista Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE).

Who are KalVista Pharmaceuticals' major shareholders?

KalVista Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Frazier Life Sciences Management L.P. (10.48%), Vanguard Group Inc. (5.15%), Dimensional Fund Advisors LP (2.07%), Northern Trust Corp (0.94%), Opaleye Management Inc. (0.43%) and SG Americas Securities LLC (0.40%). Insiders that own company stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Miami Jewish Federatio Greater, Michael David Smith, Paul K Audhya, Thomas Andrew Crockett and Venrock Healthcare Capital Par.
View institutional ownership trends
.

How do I buy shares of KalVista Pharmaceuticals?

Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KALV) was last updated on 3/4/2024 by MarketBeat.com Staff